Nasdaq:US$15.97 (+0.62) | HKEX:HK$25.50 (+1.40) | AIM:£2.38 (+0.13)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.